Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl Read More

2024-03-25T10:45:47-07:00June 18th, 2013|Adjuvant, Evidence, MammaPrint, MINDACT, Other|

Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub Read More

2024-03-25T10:55:06-07:00January 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|

Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer

PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Read More

2024-03-25T11:00:12-07:00May 2nd, 2010|Evidence, Healthcare Economics, MammaPrint, Other|

Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics

PUBLICATION: Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: Read More

2024-03-25T11:11:06-07:00January 24th, 2009|Evidence, MammaPrint, Other|
Go to Top